Literature DB >> 33025068

CYP-associated drug-drug interactions: A mission accomplished?

Olavi Pelkonen1, Jukka Hakkola2,3,4, Janne Hukkanen3,5, Miia Turpeinen2,6.   

Abstract

On the basis of official Finnish Medicines Authority (Fimea)-approved drug monographs, less than half of the approved small-molecule drugs between 2007 and 2016 were substrates, inhibitors or inducers of CYP enzymes, predominantly of CYP3A4. No significant unexpected, life-threatening, CYP-associated drug-drug interactions (CYP-DDIs) of newly approved drug entities have been observed in the last 10-15 years. The present analysis seems to suggest that tools to study and predict potentially significant CYP-DDIs are working and efficient.

Entities:  

Keywords:  Approved drugs; CYP; Cytochrome P450; Drug-drug interactions

Mesh：

Substances：

Year:  2020        PMID： 33025068     DOI： 10.1007/s00204-020-02912-1

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN： 0340-5761            Impact factor:   5.153


  8 in total

Review 1.  Inhibition and induction of human cytochrome P450 (CYP) enzymes.

Authors:  O Pelkonen; J Mäenpää; P Taavitsainen; A Rautio; H Raunio
Journal:  Xenobiotica       Date:  1998-12       Impact factor: 1.908

2.  Cimetidine inhibits microsomal drug metabolism in the rat.

Authors:  J Puurunen; O Pelkonen
Journal:  Eur J Pharmacol       Date:  1979-05-01       Impact factor: 4.432

3.  [Benign esophageal stenosis in ectopia of the gastric mucosa].

Authors:  H P Hebestreit; F Asmar; J Lütgemeier
Journal:  Fortschr Geb Rontgenstr Nuklearmed       Date:  1971-10

4.  Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.

Authors:  Jingjing Yu; Zhu Zhou; Jessica Tay-Sontheimer; René H Levy; Isabelle Ragueneau-Majlessi
Journal:  Drug Metab Dispos       Date:  2018-03-23       Impact factor: 3.922

5.  Pigtailed macaques (Macaca nemestrina) with trisomy X manifest physical and mental retardation.

Authors:  G C Ruppenthal; S A Caffery; B L Goodlin; G P Sackett; N V Vigfusson; V G Peterson
Journal:  Am J Ment Defic       Date:  1983-03

Review 6.  Inhibition and induction of human cytochrome P450 enzymes: current status.

Authors:  Olavi Pelkonen; Miia Turpeinen; Jukka Hakkola; Paavo Honkakoski; Janne Hukkanen; Hannu Raunio
Journal:  Arch Toxicol       Date:  2008-07-11       Impact factor: 5.153

7.  Effect of cimetidine on microsomal drug metabolism in man.

Authors:  J Puurunen; E Sotaniemi; O Pelkonen
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953

Review 8.  Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.

Authors:  Jingjing Yu; Ichiko D Petrie; René H Levy; Isabelle Ragueneau-Majlessi
Journal:  Drug Metab Dispos       Date:  2018-11-15       Impact factor: 3.922
  8 in total
  2 in total

1.  Characterization of furathiocarb metabolism in in-vitro human liver microsomes and recombinant cytochrome P450 enzymes.

Authors:  Khaled Abass; Petri Reponen; Walaa F Alsanie; Arja Rautio; Olavi Pelkonen
Journal:  Toxicol Rep       Date:  2022-04-01

2.  An approach for mixture testing and prioritization based on common kinetic groups.

Authors:  Albert Braeuning; Denise Bloch; Mawien Karaca; Carsten Kneuer; Stefanie Rotter; Tewes Tralau; Philip Marx-Stoelting
Journal:  Arch Toxicol       Date:  2022-03-19       Impact factor: 6.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.